In the article "Is COVID-19 receiving ADE from other coronaviruses?" author has suggested the possibility of antibody dependent enhancement (ADE) of SARS-COV-2 disease (COVID-19) as a potential mechanism of the increase severity of the disease [1]. Although it's an interesting hypothesis, we should be careful in attributing ADE to enhanced severity of the current disease. As viruses from same group share cross reactivity, it is not uncommon to have cross reactive antibody responses [2] . Outside of the dengue virus serotypes family, which has demonstrated ADE in animal models, the ADE of the viruses using sub-neutralizing antibody levels has largely been restricted to in-vitro experiments. Cell culture experiments are considered pre-requisite to moving forward to animal experiments, however, not always result is translated to in-vivo setup. There is lack of collective innate/adaptive immune response in-vitro, which is presented in-vivo and the intricate interactions drive the disease pathology. Deliberate reduction in the neutralizing antibody levels in in-vitro assays and lack of innate immune response from other cells may result in an artificial ADE in cell-culture. As COVID-19 spread across the globe a common pattern of underlying morbid conditions such as diabetes and cardiovascular conditions is appearing. Such underlying conditions are known to present immune response dysfunction [3, 4] . As reported by Channappanavar et.al, immune dysregulation may contribute to lethal pneumonia induction by SARS-CoV [5] . To date, vaccines are the most effective way of protecting against infectious diseases. Improper attribution of ADE in the absence of robust demonstration in animal models may hinder/scuttle the efforts to develop effective vaccines against COVID-19 and or other viruses of human health importance.
